Keyphrases
Acute Myeloid Leukemia
100%
Myelodysplastic Syndrome
65%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
25%
Hematopoietic Stem Cells
22%
FMS-like Tyrosine Kinase 3 (FLT3)
20%
Azacitidine
19%
Overall Survival
18%
All-trans Retinoic Acid
16%
Complete Remission
16%
Peripheral Blood
15%
FLT3 Internal Tandem Duplication
12%
Lenalidomide
12%
Low-risk Myelodysplastic Syndromes
12%
Clonal Hematopoiesis
12%
Leukemia Patients
12%
Prognostic Impact
11%
Bone Marrow
11%
Leukemia
10%
Minimal Residual Disease
10%
Intensive Chemotherapy
10%
Multiple Myeloma
10%
Nucleophosmin 1 (NPM1)
9%
FLT3-ITD
9%
CD34+
9%
Phase II Trial
9%
Hematopoiesis
8%
Secondary Acute Myeloid Leukemia (sAML)
8%
Gemtuzumab Ozogamicin
8%
Chemotherapy
8%
Newly Diagnosed
8%
CD34+ Cells
8%
Phase II Study
8%
High-risk Myelodysplastic Syndrome
8%
Hazard Ratio
7%
Placebo
7%
Austrian
7%
C-X-C Chemokine Receptor Type 4 (CXCR4)
7%
High Risk
7%
Older Patients
7%
High-dose Cytarabine
7%
International Prognostic Scoring System
7%
Decitabine
6%
Hypomethylating Agents
6%
Relapsed or Refractory Acute Myeloid Leukemia
6%
Stromal Cells
6%
Hematological Malignancies
6%
Progenitor Cells
6%
Luspatercept
6%
Induction Therapy
6%
Cytarabine
6%
Medicine and Dentistry
Acute Myeloid Leukemia
70%
Myelodysplastic Syndrome
49%
Azacitidine
21%
Overall Survival
16%
Hematopoietic Cell
14%
Tretinoin
12%
Cell Transplantation
11%
Hematopoiesis
11%
Acute Myelogenous Leukemia
10%
Leukemia
10%
Cytarabine
10%
NPM1
9%
Minimal Residual Disease
8%
Diseases
7%
Arm
7%
Allogeneic Hematopoietic Stem Cell Transplantation
7%
Hypomethylating Agent
6%
Secondary Acute Myeloid Leukemia
6%
Placebo
6%
Gemtuzumab Ozogamicin
6%
Luspatercept
6%
Anemia
6%
Midostaurin
6%
In Vitro
6%
Sorafenib
6%
Event Free Survival
5%
Lenalidomide
5%
Hazard Ratio
5%
Allogeneic Stem Cell Transplantation
5%
Multiple Myeloma
5%
Cancer
5%
International Prognostic Scoring System
5%
Prognostic Factor
5%
Decitabine
5%
Neoplasm
5%
Drug Megadose
5%